Phase II Trial of Outpatient Intravenous Interleukin-2 in Malignant Melanoma and Metastatic Kidney Cancer
The current study will test single agent IL-2 given daily for 4 doses every 3 weeks for a
total of 12 doses in an outpatient setting in stage IV melanoma and kidney cancer to attempt
to determine the response rate, how long the responses last, and median survival of this
regimen in these two diseases. Responding patients and those with absence of disease
progression may receive additional cycles of therapy every 3 weeks.
Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Walter Quan, Jr., M.D.
Loma Linda University Cancer Center
United States: Institutional Review Board
|Loma Linda University Cancer Center||Loma Linda, California 92354|
|Highland Springs Medical Plaza||Beaumont, California 92223|